# Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

> **NCT03889366** · PHASE1 · COMPLETED · sponsor: **Nuformix Technologies Limited** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Aprepitant 125 mg

## Key facts

- **NCT ID:** NCT03889366
- **Lead sponsor:** Nuformix Technologies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2019-04-15
- **Final completion:** 2019-04-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03889366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03889366, "Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03889366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*